In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapiesNancy E. Sealover, Robert L. Kortum|iScience|2023Cited by 14
Wild-type RAS signaling is an essential therapeutic target in <i>RAS</i> -mutated cancersNancy E. Sealover, Robert L. Kortum|Science Signaling|2025Cited by 3
In situ modeling of acquired resistance to RTK/RAS pathway targeted therapiesNancy E. Sealover, Robert L. Kortum|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 2